~(153)Sm-EDTMP治疗恶性肿瘤骨转移的临床评价

①目的评价放射性核素１５３钐－乙二胺四甲撑膦酸（１５３Ｓｍ－ＥＤＴＭＰ）治疗恶性肿瘤骨转移的疗效和副作用。②方法用１５３Ｓｍ－ＥＤＴＭＰ对１６８例骨转移的病人进行内照射治疗，剂量２９．６～３７．０ＭＢｑ／ｋｇ，观察治疗前后骨痛、血清碱性磷酸酶（ＡＬＰ）、血细胞及病灶的变化。③结果１６８例病人中１４３例（８５．１％）骨痛缓解；随访２２例病人有７例（３１．８％）病人骨转移灶钙化和消除；治疗后病人末梢血白细胞、血小板、红细胞和血红蛋白较治疗前均有显著性降低（ｔ＝８．１９，７．３９，５．００，４．１５，Ｐ均＜０．００１）。④结论１５３Ｓｍ－ＥＤＴＭＰ治疗转移性骨肿瘤有明显缓解骨痛、控制病情进展和消除病灶的作用，同时有暂时降低血细胞的副作用。

CLINICAL EVALUATION OF 153Sm-EDTMP IN THE TREATMENT OF OSSEOUS METASTASIS OF MALIGNANT TUMORS

Objective To evaluate the effects and side-effects of samarium-153-ethylenediamine tetramethylene phospho- nnic acid (153Sm-EDTMP) in the treatment of osseous metastasis of malignant tumors. Methods 168 patients with osseous metastasis underwent treatment using 153Sm-EDTMP ranged from 29. 6 to 37. 0 MBq/kg. The changes of bone pain, blood pic- tures and metstasis foci were observed before and after the treatment. Results After treatment,143 out of 168 cases.85. 1%) experienced osteodynia relief. Calcification and disappearance of metastasis foci was found in 7 out of 22 follow-up patients. The counts of WBC , PLT, RBC and Hb concentration decreased significantly comparied with that before the treatment (t= 8.19 , 7.39, 5.00, 4.15. P<0.O01). Conclusion Treatment of malignant tumor osseous metastasis using 153Sm-EDTMP had efficiency in osteodynia relief, metastasis foci contrcol. but induces temporary decrement of peripheral blood cells.